Yaron Werber Recent News
Gilead's HepC Drug Sales May Be More Resilient Than Feared
Citi Maintains on Intercept Pharmaceuticals
UPDATE: Citigroup Reiterates on Celgene Following Detailed Analysis
UPDATE: Citigroup Reiterates on Amgen Following Detailed Market Analysis
UPDATE: Citigroup Reiterates on Gilead Sciences on Positive Outlook
UPDATE: Citigroup Raises PT on Amgen Following Onyx Acquisition
Citi Lowers Genzyme (GENZ) Price Target
Citi Rates Rates Amgen (AMGN) A Medium Risk Buy
31.8% Return Expected in Gilead Sciences, Further Upside Possible (GILD)
Hematide To Pose Threat to AMGN's Base Business From Late 2011